Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Trial ID or NCT#
Status
Purpose
This molecular biology and phase II trial studies how well imetelstat sodium works in treating younger patients with recurrent or refractory brain tumors. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Official Title
A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Pediatric Hematology/Oncology
650-723-5535
View on ClinicalTrials.gov